Fekal Mikrobiyota Transplantasyonu
Özet
Fekal mikrobiyota transplantasyonu (FMT), sağlıklı bir donörden alınan dışkının intestinal mikrobiyota dengesini yeniden sağlamak amacıyla hasta bir alıcıya aktarılması işlemidir. Günümüzde antibiyotiğe dirençli Clostridium difficile enfeksiyonu tedavisinde onaylanmış ve yüksek başarı oranına sahip bir yöntem olarak kullanılmaktadır. Tedavinin obezite, diyabet ve nöropsikiyatrik bozukluklar gibi gastrointestinal sistem dışı hastalıklarda da etkili olabileceğine dair çalışmalar devam etmekle birlikte, uzun dönem yan etkileri henüz tam olarak bilinmemektedir.
Fecal microbiota transplantation (FMT) is the process of transferring stool from a healthy donor into the intestinal lumen of a patient to restore microbial balance. It is currently an approved and highly successful treatment for antibiotic-resistant recurrent Clostridium difficile infections. While research suggests potential efficacy in non-gastrointestinal conditions such as obesity, diabetes, and neuropsychiatric disorders, the long-term side effects and full impact of the procedure remain to be established through further controlled studies.
Referanslar
Mcllroy JR, Segal JP, Mullish BH, Current and future targets for faecal microbiota transplantation, Human Microbiome Journal, 2019, (11) , Doi: 10.1016/2018.08.004
Ünal NG, Fekal Mikrobiyota Transplantasyonu, Güncel Gastroenteroloji, 2016, 20(4), 437-441
Grigoryan Z, Shen MJ, Twardus SW, Fecal microbiota transplantation: Uses, questions, and ethics. Medicine in Microecology, 2020, (6),
Borody TJ, Ramakha S, Fecal microbiata transplantation for treatment of Clostridies difficilie infection, 2021,
Nood EV, Vrieze A, Nieuwdrop M, Tekrarlayan Clostridium difficilie için donör dışkısının duodenal infüzyonu, New England Journal of Medicine, 5(368), 407-415
Wang JW, Kuo CH, Kuo FC, Fecal microbiota transplantation: Rewiev and update, Journal of the Formosan Medical Association, 2019, (118), S32-S31. Doi: 10.1016/2016.08.011
Uygun A, Fekal Mikrobiyota Transplantasyonu, Journal of Biotechnology and Strategic Health Research, 2017, (1), 132-140.
Altamirano JG, Garza HJM, Gonzalez EG, Fecal microbiata transplantation, Medicina Universitaria, 2015, 68(17), 192-194.
Carlucci C, Petrof EO, Vercoe EA, Fecal Microbiota-based Therapeutics for Recurrent Clostridium difficile Infection, Ulcerative Colitis and Obesity, EBioMedicine, 2016, (13), 37-45.
Singh R, Nieuwdrop M, Berge IJMten, The potential beneficial role of faecal microbiota transplantation in diseases order than Clostridium difficilie infection, Clinical Microbiology and Infection, 11(20), 1119-1125, Doi: 10.1111/1469-069.12799
Scala K, Doboszewska U, Szopa A, The role of microbiota-gut-brain axis in neuropsychiatric and neurological disorders, Pharmacological Research, 2021 (172), Doi: 10.1016/2021.105840
Sehgal EJ, Andreasson A, The gut microbiota and mental health in adults, Current Opinion in Neurobiology, 2020, (62), 102-114.
Çelebi G, Uygun A, İntestinal Mikrobiyota ve Fekal Transplantasyon, Güncel Gastroenteroloji, 2013, 17(2), 148-158.
